{
    "nct_id": "NCT01079819",
    "title": "Randomized, Placebo-controlled, Double-blind, Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 in Healthy Young Male and Elderly Male and Female Chinese Subjects",
    "status": "COMPLETED",
    "last_update_time": "2011-02-04",
    "description_brief": "The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "BMS-708163 (avagacestat) \u2014 oral small-molecule \u03b3-secretase inhibitor targeting amyloid-\u03b2 production"
    ],
    "placebo": [
        "Placebo \u2014 used as control in the randomized, placebo-controlled study"
    ],
    "explanation_target": [
        "Reason: BMS-708163 (avagacestat) is an oral, small-molecule \u03b3-secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 (A\u03b2) peptides (a disease-modifying approach targeting AD pathology). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act: Extracted details \u2014 the trial you provided is a randomized, placebo-controlled, double-blind single- and multiple-dose PK/safety study of BMS-708163 in healthy Chinese subjects; literature confirms BMS-708163 = avagacestat, a \u03b3\u2011secretase inhibitor being developed for Alzheimer\u2019s disease. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 because the drug is a small-molecule \u03b3\u2011secretase inhibitor that aims to lower A\u03b2 (pathology-targeted, potentially disease-modifying), it fits the 'disease-targeted small molecule' category rather than a cognitive enhancer or symptomatic neuropsychiatric treatment. Note: prior clinical studies reported safety/tolerability concerns and limited efficacy signals in Phase II, which is consistent with the drug having been evaluated as a disease-targeting small molecule. \ue200cite\ue202turn0search2\ue202turn0search4\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: BMS-708163 (avagacestat) is an orally bioavailable, small\u2011molecule \u03b3\u2011secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 (A\u03b2) peptides \u2014 a disease\u2011modifying approach that directly targets A\u03b2 generation. \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "Act: Extracted details \u2014 the provided trial is a randomized, placebo\u2011controlled, double\u2011blind single\u2011 and multiple\u2011dose PK/safety study of BMS\u2011708163 (avagacestat) in healthy subjects; literature and product pages confirm BMS\u2011708163 = avagacestat and that it inhibits \u03b3\u2011secretase to lower A\u03b2. (Relevant PK/safety studies and compound profiles support these facts.) \ue200cite\ue202turn0search2\ue202turn0search6\ue202turn0search4\ue201",
        "Reflect: Classification check \u2014 because the drug\u2019s mechanism is inhibition of \u03b3\u2011secretase to lower A\u03b2 production, the most specific CADRO match is A) Amyloid beta. Phase\u20112 development and safety/tolerability issues (dose\u2011dependent adverse events and limited efficacy signals) are documented but do not change the target classification. \ue200cite\ue202turn1search0\ue202turn1search1\ue201",
        "Web search sources (key results used): - Discovery / mechanism (\u03b3\u2011secretase inhibitor, APP/A\u03b2 selectivity): ACS Medicinal Chemistry Letters (discovery of BMS\u2011708163). \ue200cite\ue202turn0search3\ue201 - PK/safety single\u2011dose and age\u2011group study: British Journal of Clinical Pharmacology / PMC article. \ue200cite\ue202turn0search2\ue201 - Multicenter single\u2011ascending dose PK/tolerability study (PubMed summary). \ue200cite\ue202turn0search6\ue201 - Compound/product profiles confirming potency/selectivity: Tocris / MedChemExpress product pages. \ue200cite\ue202turn0search1\ue202turn0search4\ue201 - Phase\u20112 safety/tolerability and development discontinuation reports: PubMed Phase\u20112 safety paper and trial reports / termination summaries. \ue200cite\ue202turn1search0\ue202turn1search3\ue201"
    ]
}